AG Human Induced Pluripotent Stem (iPS) Cell Laboratory
Leiter: Dr. Dr. M. B.ELSaied
Mitarbeiter: Hr. A. G. Delgado, Hr. A. Kumar
Disease modeling with induced pluripotent stem (iPS) cells has garnered great attention, as the biologic characteristics of iPS cells have matched the scientific needs for such cells in medical research. Both human iPS cells and embryonic stem (ES) cells are biologically very similar but have different origins. Two groups (Yamanaka group in Kyoto University and Thomson group in University of Wisconsin) separately reported that somatic cells can be successfully reprogrammed into iPS cells. In each study, four transcription factors were used for induction. Yamanaka’s group selected Oct3/4, Sox2, Klf, and c-Myc. While, Thomson’s group used Oct3/4, Sox2, Nanog, and Lin28. The generation of human iPS cell-derived cardiomyocytes is of growing interest for multiple applications. First, access to an in vitro model of human development permits the study of human heart development in ways not otherwise possible. Second, stem cell-derived cardiomyocytes serve as a human cardiac model that can be used for diverse basic research studies ranging from cellular electrophysiology to protein biochemistry. Furthermore, human iPS cells have a couple of key advantages: they avoid the ethical concerns that have plagued the ES cell field and they are patient-specific.
Disease modeling using human iPS Cell.
Molecular mechanisms responsible for human cardiomyopathies.
Metabolic and mitochondrial oxidative stress analysis.
Human adipose-derived stem cells self-renewal and differentiation to cardiovascular tissues
Reprogramming of somatic cells towards iPS cells-derived cardiomyocytes
Mitochondrial respiration and energy phenotype of human iPS cells-derived cardiomyocytes after metabolic selection